Patents by Inventor Michael P. Byrne

Michael P. Byrne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7786285
    Abstract: This invention is directed to preparation and expression of synthetic genes encoding polypeptides containing protective epitopes of botulinum neurotoxin (BoNT). The invention is also directed to production of immunogenic peptides encoded by the synthetic genes, as well as recovery and purification of the immunogenic peptides from recombinant organisms. The invention is also directed to methods of vaccination against botulism using the expressed peptides.
    Type: Grant
    Filed: May 19, 2006
    Date of Patent: August 31, 2010
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Leonard A. Smith, Michael P. Byrne, John L. Middlebrook, Hugh Lapenotiere, Michael A. Clayton, Douglas R. Brown
  • Patent number: 7407935
    Abstract: Disclosed herein are polypeptides and variants thereof comprising a polypeptide sequence having substantial identity to ricin A chain (RTA) that lack detectable N-glycosidase-rRNA activity or exhibit reduced N-glycosidase-rRNA activity as compared to controls and methods of making and using thereof. The polypeptides and variants have a greater solubility in aqueous solutions of physiological pH and ionic strength than RTA and also retain the integrity of the neutralizing immunological epitope of wild type RTA. Also disclosed are immunogenic compositions that may be used to immunize a subject against ricin intoxication. Methods of immunizing against, treating, and preventing ricin intoxication are disclosed.
    Type: Grant
    Filed: August 23, 2004
    Date of Patent: August 5, 2008
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Mark A. Olson, Charles B. Millard, Michael P. Byrne, Robert W. Wannemacher
  • Patent number: 7214787
    Abstract: This invention is directed to preparation and expression of synthetic genes encoding polypeptides containing protective epitopes of botulinum neurotoxin (BoNT). The invention is also directed to production of immunogenic peptides encoded by the synthetic genes, as weel as recovery and purification of the immunogenic peptides from recombinant organisms. The invention is also directed to methods of vaccination against botulism using the expressed peptides.
    Type: Grant
    Filed: July 6, 2000
    Date of Patent: May 8, 2007
    Assignee: United States of America as Represented by the Secretary of the Army
    Inventors: Leonard A. Smith, Michael P. Byrne, John L. Middlebrook, Hugh Lapenotiere, Michael A. Clayton, Douglas R. Brown
  • Patent number: 7081529
    Abstract: This invention is directed to preparation and expression of synthetic genes encoding polypeptides containing protective epitopes of botulinum neurotoxin (BoNT). The invention is also directed to production of immunogenic peptides encoded by the synthetic genes, as weel as recovery and purification of the immunogenic peptides from recombinant organisms. The invention is also directed to methods of vaccination against botulism using the expressed peptides.
    Type: Grant
    Filed: July 20, 2001
    Date of Patent: July 25, 2006
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Leonard A. Smith, Michael P. Byrne, John L. Middlebrook, Hugh Lapenotiere, Michael A. Clayton, Douglas R. Brown
  • Patent number: 6869787
    Abstract: Disclosed herein are polypeptides and variants thereof comprising a polypeptide sequence having substantial identity to ricin A chain (RTA) that lack detectable N-glycosidase-rRNA activity or exhibit reduced N-glycosidase-rRNA activity as compared to controls and methods of making and using thereof. The polypeptides and variants have a greater solubility in aqueous solutions of physiological pH and ionic strength than RTA and also retain the integrity of the neutralizing immunological epitope of wild type RTA. Also disclosed are immunogenic compositions that may be used to immunize a subject against ricin intoxication. Methods of immunizing against, treating, and preventing ricin intoxication are disclosed.
    Type: Grant
    Filed: February 27, 2002
    Date of Patent: March 22, 2005
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Mark A. Olson, Charles B. Millard, Michael P. Byrne, Robert W. Wannemacher, Ross D. LeClaire
  • Publication number: 20030181665
    Abstract: Disclosed herein are polypeptides and variants thereof comprising a polypeptide sequence having substantial identity to ricin A chain (RTA) that lack detectable N-glycosidase-rRNA activity or exhibit reduced N-glycosidase-rRNA activity as compared to controls and methods of making and using thereof. The polypeptides and variants have a greater solubility in aqueous solutions of physiological pH and ionic strength than RTA and also retain the integrity of the neutralizing immunological epitope of wild type RTA. Also disclosed are immunogenic compositions that may be used to immunize a subject against ricin intoxication. Methods of immunizing against, treating, and preventing ricin intoxication are disclosed.
    Type: Application
    Filed: February 27, 2002
    Publication date: September 25, 2003
    Inventors: Mark A. Olson, Charles B. Millard, Michael P. Byrne, Robert W. Wannemacher, Ross D. LeClaire
  • Publication number: 20030009025
    Abstract: This invention is directed to preparation and expression of synthetic genes encoding polypeptides containing protective epitopes of botulinum neurotoxin (BoNT). The invention is also directed to production of immunogenic peptides encoded by the synthetic genes, as weel as recovery and purification of the immunogenic peptides from recombinant organisms. The invention is also directed to methods of vaccination against botulism using the expressed peptides.
    Type: Application
    Filed: July 20, 2001
    Publication date: January 9, 2003
    Inventors: Leonard A. Smith, Michael P. Byrne, John L. Middlebrook, Hugh Lapenotiere, Michael A. Clayton, Douglas R. Brown
  • Patent number: D729813
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: May 19, 2015
    Inventor: Michael P. Byrne